Abbvie - Striving for remission with JAK inhibition in the management of rheumatoid arthritis

Industry room 4
Satellite Symposia
04 June 2021 08:15 - 09:45

Learning Objective(s):  
  • To introduce remission as an important measure of therapeutic benefit in patients with rheumatoid arthritis receiving therapeutic treatments 
  • To highlight that there are multiple definitions used to identify patients in remission (DAS28-CRP, CDAI, SDAI, and Boolean) and to explore the clinical differences these represent, with reference to specific patient examples 
  • To provide an overview of the available evidence regarding the ability to elevate levels or remission with JAK inhibitors to elevate levels of remission compared with biologic standard of care, according to multiple definitions of remission in patients with rheumatoid arthritis. 


Title Time Calendar .ics
Welcome and introduction
04 June 2021 08:15 - 08:25 .ics
What defines remission and how good are we at achieving it?
04 June 2021 08:25 - 08:45 .ics
What’s the value of achieving remission?
04 June 2021 08:45 - 09:00 .ics
Can JAK inhibitors elevate more patients to achieve robust remission?
04 June 2021 09:00 - 09:15 .ics
Understanding the risks: The evolving safety profile of JAK inhibitors in rheumatoid arthritis
04 June 2021 09:15 - 09:35 .ics